Pressure to “do something with AI” is loud, but the stakes are higher when patient data, regulators, and legacy systems meet non‑deterministic models. We sat down with the hosts of the Enterprise Architecture Experience podcast — Hassan Abba from AstraZeneca and Jon Hill from Alvotech — to compare how a global R&D giant and a thousand‑person biopharma scale-up are making AI useful without trading away trust. The conversation gets practical fast: where AI speeds discovery, where it should never touch regulated data, and how to draw clean lines that everyone can work with.
